CROSS COUNTRY HEALTHCARE INC (CCRN) Fundamental Analysis & Valuation

NASDAQ:CCRN • US2274831047

Current stock price

10.12 USD
-0.15 (-1.46%)
At close:
10.12 USD
0 (0%)
After Hours:

This CCRN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. CCRN Profitability Analysis

1.1 Basic Checks

  • In the past year CCRN was profitable.
  • In the past year CCRN had a positive cash flow from operations.
  • In multiple years CCRN reported negative net income over the last 5 years.
  • Of the past 5 years CCRN 4 years had a positive operating cash flow.
CCRN Yearly Net Income VS EBIT VS OCF VS FCFCCRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M

1.2 Ratios

  • The Return On Assets of CCRN (-21.13%) is worse than 80.00% of its industry peers.
  • CCRN's Return On Equity of -29.38% is on the low side compared to the rest of the industry. CCRN is outperformed by 68.00% of its industry peers.
  • CCRN has a Return On Invested Capital of 0.54%. This is in the lower half of the industry: CCRN underperforms 63.00% of its industry peers.
  • CCRN had an Average Return On Invested Capital over the past 3 years of 6.06%. This is below the industry average of 8.40%.
  • The last Return On Invested Capital (0.54%) for CCRN is well below the 3 year average (6.06%), which needs to be investigated, but indicates that CCRN had better years and this may not be a problem.
Industry RankSector Rank
ROA -21.13%
ROE -29.38%
ROIC 0.54%
ROA(3y)-4.3%
ROA(5y)5%
ROE(3y)-5.84%
ROE(5y)13.62%
ROIC(3y)6.06%
ROIC(5y)14.51%
CCRN Yearly ROA, ROE, ROICCCRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40

1.3 Margins

  • CCRN's Operating Margin of 0.24% is on the low side compared to the rest of the industry. CCRN is outperformed by 63.00% of its industry peers.
  • CCRN's Operating Margin has declined in the last couple of years.
  • CCRN's Gross Margin of 20.26% is in line compared to the rest of the industry. CCRN outperforms 47.00% of its industry peers.
  • In the last couple of years the Gross Margin of CCRN has declined.
Industry RankSector Rank
OM 0.24%
PM (TTM) N/A
GM 20.26%
OM growth 3Y-71.15%
OM growth 5Y-31.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.25%
GM growth 5Y-3.52%
CCRN Yearly Profit, Operating, Gross MarginsCCRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. CCRN Health Analysis

2.1 Basic Checks

  • CCRN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for CCRN has been reduced compared to 1 year ago.
  • The number of shares outstanding for CCRN has been reduced compared to 5 years ago.
  • CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CCRN Yearly Shares OutstandingCCRN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
CCRN Yearly Total Debt VS Total AssetsCCRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • CCRN has an Altman-Z score of 4.90. This indicates that CCRN is financially healthy and has little risk of bankruptcy at the moment.
  • CCRN has a better Altman-Z score (4.90) than 86.00% of its industry peers.
  • There is no outstanding debt for CCRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.9
ROIC/WACC0.06
WACC9.06%
CCRN Yearly LT Debt VS Equity VS FCFCCRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 3.78 indicates that CCRN has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 3.78, CCRN belongs to the best of the industry, outperforming 88.00% of the companies in the same industry.
  • A Quick Ratio of 3.78 indicates that CCRN has no problem at all paying its short term obligations.
  • The Quick ratio of CCRN (3.78) is better than 91.00% of its industry peers.
Industry RankSector Rank
Current Ratio 3.78
Quick Ratio 3.78
CCRN Yearly Current Assets VS Current LiabilitesCCRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CCRN Growth Analysis

3.1 Past

  • CCRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -95.56%.
  • Measured over the past years, CCRN shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -46.59% on average per year.
  • Looking at the last year, CCRN shows a very negative growth in Revenue. The Revenue has decreased by -21.56% in the last year.
  • Measured over the past years, CCRN shows a small growth in Revenue. The Revenue has been growing by 4.74% on average per year.
EPS 1Y (TTM)-95.56%
EPS 3Y-84.39%
EPS 5Y-46.59%
EPS Q2Q%-250%
Revenue 1Y (TTM)-21.56%
Revenue growth 3Y-27.85%
Revenue growth 5Y4.74%
Sales Q2Q%-23.61%

3.2 Future

  • CCRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 122.11% yearly.
  • CCRN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.14% yearly.
EPS Next Y455.34%
EPS Next 2Y271.84%
EPS Next 3Y175.5%
EPS Next 5Y122.11%
Revenue Next Year-8.87%
Revenue Next 2Y-2.17%
Revenue Next 3Y0.18%
Revenue Next 5Y2.14%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CCRN Yearly Revenue VS EstimatesCCRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
CCRN Yearly EPS VS EstimatesCCRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

4

4. CCRN Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 506.00, CCRN can be considered very expensive at the moment.
  • CCRN's Price/Earnings ratio is a bit more expensive when compared to the industry. CCRN is more expensive than 60.00% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of CCRN to the average of the S&P500 Index (26.77), we can say CCRN is valued expensively.
  • The Price/Forward Earnings ratio is 91.12, which means the current valuation is very expensive for CCRN.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of CCRN indicates a slightly more expensive valuation: CCRN is more expensive than 62.00% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of CCRN to the average of the S&P500 Index (21.75), we can say CCRN is valued expensively.
Industry RankSector Rank
PE 506
Fwd PE 91.12
CCRN Price Earnings VS Forward Price EarningsCCRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300 400 500

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CCRN is valued a bit cheaper than the industry average as 68.00% of the companies are valued more expensively.
  • CCRN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CCRN is cheaper than 87.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.13
EV/EBITDA 11.48
CCRN Per share dataCCRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • CCRN's earnings are expected to grow with 175.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.11
PEG (5Y)N/A
EPS Next 2Y271.84%
EPS Next 3Y175.5%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CCRN Dividend Analysis

5.1 Amount

  • CCRN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CCRN Fundamentals: All Metrics, Ratios and Statistics

CROSS COUNTRY HEALTHCARE INC

NASDAQ:CCRN (4/30/2026, 5:21:36 PM)

After market: 10.12 0 (0%)

10.12

-0.15 (-1.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Industry Strength45.96
Industry Growth88.2
Earnings (Last)03-04
Earnings (Next)05-07
Inst Owners83.99%
Inst Owner Change0.02%
Ins Owners7.09%
Ins Owner Change17.24%
Market Cap325.86M
Revenue(TTM)1.05B
Net Income(TTM)-94.85M
Analysts74.67
Price Target11.9 (17.59%)
Short Float %3.84%
Short Ratio2.38
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-157.94%
Min EPS beat(2)-296.08%
Max EPS beat(2)-19.79%
EPS beat(4)1
Avg EPS beat(4)-107.17%
Min EPS beat(4)-296.08%
Max EPS beat(4)5.59%
EPS beat(8)3
Avg EPS beat(8)-61.22%
EPS beat(12)6
Avg EPS beat(12)-39.22%
EPS beat(16)10
Avg EPS beat(16)-25.76%
Revenue beat(2)0
Avg Revenue beat(2)-9.09%
Min Revenue beat(2)-9.46%
Max Revenue beat(2)-8.72%
Revenue beat(4)0
Avg Revenue beat(4)-7.87%
Min Revenue beat(4)-9.46%
Max Revenue beat(4)-5.84%
Revenue beat(8)0
Avg Revenue beat(8)-4.22%
Revenue beat(12)2
Avg Revenue beat(12)-2.78%
Revenue beat(16)5
Avg Revenue beat(16)-1.59%
PT rev (1m)2.55%
PT rev (3m)1.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-388.87%
EPS NY rev (1m)13.77%
EPS NY rev (3m)-7.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.76%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-3.67%
Valuation
Industry RankSector Rank
PE 506
Fwd PE 91.12
P/S 0.31
P/FCF 8.13
P/OCF 6.75
P/B 1.01
P/tB 1.41
EV/EBITDA 11.48
EPS(TTM)0.02
EY0.2%
EPS(NY)0.11
Fwd EY1.1%
FCF(TTM)1.25
FCFY12.3%
OCF(TTM)1.5
OCFY14.81%
SpS32.74
BVpS10.03
TBVpS7.19
PEG (NY)1.11
PEG (5Y)N/A
Graham Number2.12403 (-79.01%)
Profitability
Industry RankSector Rank
ROA -21.13%
ROE -29.38%
ROCE 0.68%
ROIC 0.54%
ROICexc 0.76%
ROICexgc 1.17%
OM 0.24%
PM (TTM) N/A
GM 20.26%
FCFM 3.8%
ROA(3y)-4.3%
ROA(5y)5%
ROE(3y)-5.84%
ROE(5y)13.62%
ROIC(3y)6.06%
ROIC(5y)14.51%
ROICexc(3y)6.35%
ROICexc(5y)14.73%
ROICexgc(3y)10.08%
ROICexgc(5y)21.91%
ROCE(3y)7.68%
ROCE(5y)18.37%
ROICexgc growth 3Y-70.95%
ROICexgc growth 5Y-31.89%
ROICexc growth 3Y-71.51%
ROICexc growth 5Y-28.12%
OM growth 3Y-71.15%
OM growth 5Y-31.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.25%
GM growth 5Y-3.52%
F-Score6
Asset Turnover2.35
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 48.59%
Cap/Sales 0.77%
Interest Coverage 1.82
Cash Conversion 249.59%
Profit Quality N/A
Current Ratio 3.78
Quick Ratio 3.78
Altman-Z 4.9
F-Score6
WACC9.06%
ROIC/WACC0.06
Cap/Depr(3y)57.55%
Cap/Depr(5y)63.04%
Cap/Sales(3y)0.7%
Cap/Sales(5y)0.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-95.56%
EPS 3Y-84.39%
EPS 5Y-46.59%
EPS Q2Q%-250%
EPS Next Y455.34%
EPS Next 2Y271.84%
EPS Next 3Y175.5%
EPS Next 5Y122.11%
Revenue 1Y (TTM)-21.56%
Revenue growth 3Y-27.85%
Revenue growth 5Y4.74%
Sales Q2Q%-23.61%
Revenue Next Year-8.87%
Revenue Next 2Y-2.17%
Revenue Next 3Y0.18%
Revenue Next 5Y2.14%
EBIT growth 1Y103.69%
EBIT growth 3Y-79.18%
EBIT growth 5Y-28.09%
EBIT Next Year307.2%
EBIT Next 3Y80.75%
EBIT Next 5Y50.41%
FCF growth 1Y-64.01%
FCF growth 3Y-31.6%
FCF growth 5Y12.15%
OCF growth 1Y-59.83%
OCF growth 3Y-28.87%
OCF growth 5Y12.15%

CROSS COUNTRY HEALTHCARE INC / CCRN Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CROSS COUNTRY HEALTHCARE INC (CCRN) stock?

ChartMill assigns a fundamental rating of 4 / 10 to CCRN.


What is the valuation status for CCRN stock?

ChartMill assigns a valuation rating of 4 / 10 to CROSS COUNTRY HEALTHCARE INC (CCRN). This can be considered as Fairly Valued.


What is the profitability of CCRN stock?

CROSS COUNTRY HEALTHCARE INC (CCRN) has a profitability rating of 2 / 10.


What is the valuation of CROSS COUNTRY HEALTHCARE INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for CROSS COUNTRY HEALTHCARE INC (CCRN) is 506 and the Price/Book (PB) ratio is 1.01.


Can you provide the financial health for CCRN stock?

The financial health rating of CROSS COUNTRY HEALTHCARE INC (CCRN) is 9 / 10.